Article Text

Download PDFPDF
Review: response to antipsychotics in schizophrenia in published trials of limited clinical significance

Statistics from



Are the findings of trials on second-generation antipsychotics clinically relevant?


The primary measure was overall clinical change in psychiatric condition, as measured with the Clinical Global Impression change (CGI-C) score. Scores on the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) were converted to notional CGI-C scores.



Systematic review.

Data sources

References were identified from a previous systematic review of second-generation antipsychotics that included studies published up to 2001. This was supplemented by a search of MEDLINE, PsycINFO and Cumulative Index to Nursing and Allied Health Literature from 2002 to the end of 2007.

Study selection and analysis

Second-generation antipsychotic drug evaluation studies reference in previous systematic reviews, or published between 2002 and 2007. Inclusion criteria were participants with a diagnosis of schizophrenia or schizoaffective disorder, evaluation of at least one second-generation antipsychotic drug that is or has been licensed, outcome measure of change in mean PANSS and/or BPRS, a baseline PANSS score of ≥58 or a baseline BPRS score ≥31, at least a single-group pre–post …

View Full Text


  • Sources of funding None


  • Conflicting interests None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.